Based on the Purple Biotech stock forecast from 0 analysts, the average analyst target price for Purple Biotech is not available over the next 12 months. Purple Biotech’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Purple Biotech is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Purple Biotech’s stock price was USD 2.50. Purple Biotech’s stock price has changed by -2.91% over the past week, -7.41% over the past month and -79.65% over the last year.
No recent analyst target price found for Purple Biotech
No recent average analyst rating found for Purple Biotech
Company Overview Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and research collaboration with the Icahn School of Medicine for CAPTN-3 tri-specific antibody platform. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel. Read Less
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carci...Read More
Frequently Asked Questions About Purple Biotech (PPBT) Stock
Stock Target Advisor's fundamental analysis for Purple Biotech's stock is Neutral.
Unfortunately we do not have enough data on PPBT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PPBT's stock to indicate what its average analyst target is.
PPBT stock's Price/Earning ratio is 0.03.
Our analysis grades PPBT stock's Price / Earning ratio at B+. This means that PPBT stock's Price/Earning ratio is above 11% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PPBT may be undervalued for its sector.
The last closing price of PPBT's stock was USD 2.50.
The most recent market capitalization for PPBT is USD 7.27M.
Unfortunately we do not have enough analyst data on PPBT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Purple Biotech's stock.
As per our most recent records Purple Biotech has 20 Employees.
Purple Biotech's registered address is 4 Oppenheimer Street, Rehovot, Israel, 7670104.
You can get more information about it from Purple Biotech's website at https://purple-biotech.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Purple Biotech (PPBT) Stock
Stock Target Advisor's fundamental analysis for Purple Biotech's stock is Neutral.
Unfortunately we do not have enough data on PPBT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on PPBT's stock to indicate what its average analyst target is.
PPBT stock's Price/Earning ratio is 0.03.
Our analysis grades PPBT stock's Price / Earning ratio at B+. This means that PPBT stock's Price/Earning ratio is above 11% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this PPBT may be undervalued for its sector.
The last closing price of PPBT's stock was USD 2.50.
The most recent market capitalization for PPBT is USD 7.27M.
Unfortunately we do not have enough analyst data on PPBT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Purple Biotech's stock.
As per our most recent records Purple Biotech has 20 Employees.
Purple Biotech's registered address is 4 Oppenheimer Street, Rehovot, Israel, 7670104.
You can get more information about it from Purple Biotech's website at https://purple-biotech.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PPBT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
